Top Page
iSpecimen
(NASDAQ:ISPC)
iSpecimen (ISPC) vs. SPDR S&P 500 ETF (SPY)
iSpecimen Business Overview & Revenue Model
iSpecimen Earnings Call Summary
iSpecimen Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.35M | 9.29M | 9.93M | 10.40M | 11.14M | 8.18M |
| Gross Profit | 722.54K | 3.99M | 5.11M | 5.65M | 5.89M | 4.60M |
| EBITDA | -9.47M | -12.73M | -8.80M | -8.80M | -5.86M | -1.74M |
| Net Income | -11.53M | -12.50M | -11.10M | -10.25M | -8.96M | -4.65M |
Balance Sheet | ||||||
| Total Assets | 9.00M | 9.35M | 15.82M | 24.62M | 35.72M | 6.21M |
| Cash, Cash Equivalents and Short-Term Investments | 2.78M | 1.88M | 5.01M | 15.31M | 27.74M | 695.91K |
| Total Debt | 281.44K | 312.17K | 196.24K | 185.85K | 3.42M | 12.77M |
| Total Liabilities | 5.92M | 6.04M | 6.08M | 4.31M | 5.93M | 33.49M |
| Stockholders Equity | 3.07M | 3.31M | 9.74M | 20.31M | 29.79M | -27.28M |
Cash Flow | ||||||
| Free Cash Flow | -6.79M | -8.30M | -10.55M | -9.01M | -11.71M | -1.39M |
| Operating Cash Flow | -6.76M | -8.26M | -5.81M | -5.82M | -10.67M | -288.38K |
| Investing Cash Flow | -1.07M | 1.98M | -7.23M | -3.19M | -1.04M | -1.10M |
| Financing Cash Flow | 8.86M | 5.82M | 70.89K | -3.42M | 38.75M | 2.03M |
iSpecimen Technical Analysis
iSpecimen Risk Analysis
iSpecimen Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $7.52M | ― | ― | ― | ― | ― | |
39 Underperform | $6.36M | -0.07 | -296.20% | ― | -67.73% | 58.35% | |
39 Underperform | $9.40M | -0.10 | -245.18% | ― | -27.66% | 13.18% | |
37 Underperform | $6.12M | ― | -223.45% | ― | 3.26% | 65.96% | |
26 Underperform | $9.13M | ― | ― | ― | ― | ― |
iSpecimen Corporate Events
iSpecimen Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The company cites that filing within the prescribed 40-day period would require unreasonable effort or expense, prompting them to seek a five-day extension under Rule 12b-25. iSpecimen expects to file the report within this extended timeline. The company does not anticipate any significant changes in its financial results compared to the same period last year. Forward-looking statements in the notification highlight potential risks and uncertainties that could affect these expectations. The notification was signed by Katharyn Field, the Chief Executive Officer, who assures ongoing compliance efforts.
The most recent analyst rating on (ISPC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
On November 7, 2025, iSpecimen Inc. announced significant leadership changes with the appointment of Ms. Katharyn Field as Chief Executive Officer, Secretary, and Treasurer, succeeding Mr. Robert Bradley Lim who resigned from these roles and the Board. Ms. Field, who has been serving as President since February 2025, brings extensive experience in strategy consulting and executive leadership, particularly in the cannabis industry. Additionally, Mr. Arphing (Tommy) Lee was appointed as an independent director, joining the Audit and Nominating and Corporate Governance Committees. The company emphasized that these leadership changes are not expected to disrupt operations, and the Board remains focused on executing the company’s objectives.
The most recent analyst rating on (ISPC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
On October 30, 2025, iSpecimen Inc. held a special meeting of stockholders to vote on several key proposals. The company successfully approved a reverse stock split, an increase in authorized shares, and amendments related to private financing transactions and convertible securities, all of which are aimed at enhancing its financial flexibility and compliance with Nasdaq rules.
The most recent analyst rating on (ISPC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
On September 4, 2025, iSpecimen Inc. announced an update on its strategic initiative to integrate digital assets into its business model by building a $200 million corporate treasury reserve based on the Solana blockchain ecosystem. Since its initial announcement in August 2025, the company has been approached by several cryptocurrency-related companies offering opportunities in tokenized real-world assets and highly ranked cryptocurrencies. iSpecimen plans to establish a SOL-based treasury program to diversify its balance sheet and support long-term growth, with a focus on a buy and HODL strategy and purchasing locked SOL at a discount. This initiative is expected to enhance shareholder value and allow for liquidity management through partial diversification and spot trading.
The most recent analyst rating on (ISPC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.
On August 21, 2025, iSpecimen Inc. announced the successful completion of Milestone 1 in its digital transformation program, which involved the installation of the Salestack platform and the provisioning of modern infrastructure. This milestone enhances the iSpecimen Marketplace® with a cloud-native architecture, improving reliability, security, and innovation capabilities, and sets the stage for the next phase of integration aimed at achieving end-to-end operational efficiency.
The most recent analyst rating on (ISPC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.